MedPath

Investigating and comparing the effect of three therapeutic methods of Naproxen, hydroxyzine and Syrup Noscough as therapeutic methods for preventing bone pain caused by granulocyte-colony stimulating factor(GCSF )in cancer patients

Phase 3
Conditions
Bone Pain Due to PEG G-CSF.
Non-follicular lymphoma
Registration Number
IRCT20231227060538N1
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
123
Inclusion Criteria

patients with solid tumor or lymphoma Candidate for receiving Pegfilgrastim -after chemotherapy based on well known chemotherapy protocol

Exclusion Criteria

Bone metastasis in patients with progression free survival(PFS )greater than 2
Test-proven osteomalacia
chronic kidney disease or end stage renal disease patients
Patients with active rheumatic disease
diabetes
Uncontrolled thyroid disease
Patients receiving chemotherapy drugs in which bone pain is one of the complications with a high incidence of 10% (TAXAN family, bisphosphonate.)
Patients with pathological fracture or fracture due to any other reason
Opioid addicts
Contraindications for taking naproxen and methadone and other similar drugs
Vitamin D level less than 20
Paget's disease
Hyperparathyroid disease
Patients who have bone pains in the questionnaire with a score above 6 since the beginning of the project
liver disease
Patients with a history of cardiac arrhythmia
Patients who do not have the appropriate admission to fill out the pain questionnaire

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pain Score in Visual Analogue Scale(VAS) questionnaire. Timepoint: One day after the end of the first, second, third and fourth course of chemotherapy. Method of measurement: Visual Analogue Scale questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath